drugset / Trial / NCT00352261

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261

Phase 4 Completed 80 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients

Timeline

Start
2006-01
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg
Subject Lansoprazole Other / unclassified 30 mg

Indications